Amgen Establishes Commercial Operations in Brazil

By Amgen, PRNE
Thursday, April 7, 2011

Amgen Acquires Privately Held Brazilian Pharmaceutical Company Bergamo and Agrees to Reacquire Rights to Certain Amgen Products in Brazil from Hypermarcas

THOUSAND OAKS, California, April 8, 2011 - Amgen (NASDAQ: AMGN), the world's largest biotechnology company,
announced today the expansion of its operations in Brazil, including the
acquisition of Bergamo, a privately-held Brazilian pharmaceutical company.
Amgen has also agreed to reacquire rights in Brazil to its products that were
previously granted to Mantecorp (subsequently acquired by Hypermarcas).
Together, these transactions will provide Amgen a significant presence in
Brazil and immediate, direct access to one of the fastest growing
pharmaceutical markets in the world.

Bergamo is a leading supplier of medicines to the hospital sector in
Brazil with capabilities in oncology medicines and has manufacturing
facilities in Sao Paulo state. Bergamo had gross revenues of US $80 million
in 2010 and has been growing at an annual rate of 19 percent since 2007.
Under terms of the transaction announced today, Amgen gained full ownership
of Bergamo by purchasing it for approximately US $215 million.

Amgen has entered into an agreement in principle with Hypermarcas to
reacquire the rights in Brazil to several of Amgen's innovative medicines,
two of which are already approved in Brazil, Vectibix(R) (panitumumab) and
Mimpara(R) (cinacalcet), and a third, romiplostim, (registered as Nplate(R)
in the United States), a treatment for the blood disorder ITP, which is
currently under review by ANVISA, the regulatory authority in Brazil.

"Amgen's strategic goal is to make our innovative medicines available to
patients in major markets around the world," said Kevin Sharer, Amgen's
chairman and chief executive officer. "Acquiring Bergamo, a profitable
company with an established local infrastructure, and regaining the rights to
our products in Brazil, provides us an attractive entry into the Brazilian

The focus on Brazil is part of a wider international expansion strategy
for Amgen. Brazil is among the top 10 pharmaceutical markets in the world and
in recent years has been growing at a rate of about 12 percent per year. It
is expected to be the world's fifth largest pharmaceutical market by 2015.

About Amgen

Amgen discovers, develops, manufactures, and delivers innovative human
therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first
companies to realize the new science's promise by bringing safe, effective
medicines from lab to manufacturing plant to patient. Amgen therapeutics have
changed the practice of medicine, helping millions of people around the world
in the fight against cancer, kidney disease, rheumatoid arthritis, bone
disease, and other serious illnesses. With a deep and broad pipeline of
potential new medicines, Amgen remains committed to advancing science to
dramatically improve people's lives. To learn more about our pioneering
science and vital medicines, visit

Forward Looking Statements

This news release contains forward-looking statements that involve
significant risks and uncertainties, including those discussed below and
others that can be found in our Form 10-K for the year ended Dec. 31, 2010,
and in our periodic reports on Form 10-Q and Form 8-K. Amgen is providing
this information as of the date of this news release and does not undertake
any obligation to update any forward-looking statements contained in this
document as a result of new information, future events or otherwise.

No forward-looking statement can be guaranteed and actual results may
differ materially from those we project. The Company's results may be
affected by our ability to successfully market both new and existing products
domestically and internationally, clinical and regulatory developments
(domestic or foreign) involving current and future products, sales growth of
recently launched products, competition from other products (domestic or
foreign), difficulties or delays in manufacturing our products. In addition,
sales of our products are affected by reimbursement policies imposed by
third-party payors, including governments, private insurance plans and
managed care providers and may be affected by regulatory, clinical and
guideline developments and domestic and international trends toward managed
care and healthcare cost containment as well as U.S. legislation affecting
pharmaceutical pricing and reimbursement. Government and others' regulations
and reimbursement policies may affect the development, usage and pricing of
our products. Furthermore, our research, testing, pricing, marketing and
other operations are subject to extensive regulation by domestic and foreign
government regulatory authorities. We or others could identify safety, side
effects or manufacturing problems with our products after they are on the
market. Our business may be impacted by government investigations, litigation
and products liability claims. Further, while we routinely obtain patents for
our products and technology, the protection offered by our patents and patent
applications may be challenged, invalidated or circumvented by our
competitors. We depend on third parties for a significant portion of our
manufacturing capacity for the supply of certain of our current and future
products and limits on supply may constrain sales of certain of our current
products and product candidate development. In addition, we compete with
other companies with respect to some of our marketed products as well as for
the discovery and development of new products. Discovery or identification of
new product candidates cannot be guaranteed and movement from concept to
product is uncertain; consequently, there can be no guarantee that any
particular product candidate will be successful and become a commercial
product. Further, some raw materials, medical devices and component parts for
our products are supplied by sole third-party suppliers.

    Contact, Amgen
    Mary Klem, +1-805-447-6979 (U.S. media)
    Helen Mills, +41-41-3690-315 (EU media)
    Shirley Emerick +55-11-8924-8608 (Brazil media)
    Arvind Sood, +1-805-447-1060 (investors)



will not be displayed